These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 8055787

  • 1. [Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].
    Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Bolanowski M, Jedrzejak J, Milewicz A.
    Endokrynol Pol; 1993; 44(2):161-8. PubMed ID: 8055787
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.
    Plöckinger U, Quabbe HJ.
    J Endocrinol Invest; 1991 Dec; 14(11):943-8. PubMed ID: 1806612
    [Abstract] [Full Text] [Related]

  • 3. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [Abstract] [Full Text] [Related]

  • 4. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Feb; 43(3):234-41. PubMed ID: 1345564
    [Abstract] [Full Text] [Related]

  • 5. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP.
    J Endocrinol Invest; 1996 Feb; 19(7):472-9. PubMed ID: 8884542
    [Abstract] [Full Text] [Related]

  • 6. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 7. The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.
    Bolanowski M, Milewicz A, Bohdanowicz-Pawlak A, Bednarek-Tupikowska G, Jedrzejak JA, Lancranjan I.
    Endokrynol Pol; 1993 Jul; 44(4):467-76. PubMed ID: 8055815
    [Abstract] [Full Text] [Related]

  • 8. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A, Prezelj J, Vrhovec I, Lancranjan I.
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [Abstract] [Full Text] [Related]

  • 9. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
    [Abstract] [Full Text] [Related]

  • 10. Bromocriptine therapy in acromegaly. A long-term review of 35 cases.
    Sachdev Y, Gopal K, Garg VK.
    Postgrad Med J; 1981 Apr; 57(666):210-6. PubMed ID: 7027229
    [Abstract] [Full Text] [Related]

  • 11. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
    Rau H, Althoff PH, Schmidt K, Usadel KH.
    Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
    [Abstract] [Full Text] [Related]

  • 12. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
    Fossati P, Asfour M, Brion-Brevan B, Fourlinnie JC, Cappoen JP, Dalle-Furnari MA, Blacker C.
    Ann Endocrinol (Paris); 1977 Mar; 38(4):291-301. PubMed ID: 332054
    [Abstract] [Full Text] [Related]

  • 13. [Long-term use of parlodel in acromegaly].
    Pisarskaia IV, Zefirova GS, Ibragimova GV.
    Ter Arkh; 1984 Mar; 56(10):107-10. PubMed ID: 6523351
    [Abstract] [Full Text] [Related]

  • 14. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 15. Acromegaly--results of long term treatment with bromocriptine.
    Besser GM, Wass JA, Thorner MO.
    Acta Endocrinol Suppl (Copenh); 1978 Aug; 216():187-98. PubMed ID: 347861
    [Abstract] [Full Text] [Related]

  • 16. Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine.
    Jaspers C, Haase R, Pfingsten H, Benker G, Reinwein D.
    Clin Investig; 1993 Jul; 71(7):547-51. PubMed ID: 8374248
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.